Literature DB >> 19801450

Tie2-mediated loss of peroxisome proliferator-activated receptor-gamma in mice causes PDGF receptor-beta-dependent pulmonary arterial muscularization.

C Guignabert1, C M Alvira, T-P Alastalo, H Sawada, G Hansmann, M Zhao, L Wang, N El-Bizri, M Rabinovitch.   

Abstract

Peroxisome proliferator-activated receptor (PPAR)-gamma is reduced in pulmonary arteries (PAs) of patients with PA hypertension (PAH), and we reported that deletion of PPARgamma in smooth muscle cells (SMCs) of transgenic mice results in PAH. However, the sequelae of loss of PPARgamma in PA endothelial cells (ECs) are unknown. Therefore, we bred Tie2-Cre mice with PPARgamma(flox/flox) mice to induce EC loss of PPARgamma (Tie2 PPARgamma(-/-)), and we assessed PAH by right ventricular systolic pressure (RVSP), RV hypertrophy (RVH), and muscularized distal PAs in room air (RA), after chronic hypoxia (CH), and after 4 wk of recovery in RA (Rec-RA). The Tie2 PPARgamma(-/-) mice developed spontaneous PAH in RA with increased RVSP, RVH, and muscularized PAs vs. wild type (WT); both genotypes exhibited a similar degree of PAH following chronic hypoxia, but Tie2 PPARgamma(-/-) mice had more residual PAH compared with WT mice after Rec-RA. The Tie2 PPARgamma(-/-) vs. WT mice in RA had increased platelet-derived growth factor receptor-beta (PDGF-Rbeta) expression and signaling, despite an elevation in the PPARgamma target apolipoprotein E, an inhibitor of PDGF signaling. Inhibition of PDGF-Rbeta signaling with imatinib, however, was sufficient to reverse the PAH observed in the Tie2 PPARgamma(-/-) mice. Thus the disruption of PPARgamma signaling in EC is sufficient to cause mild PAH and to impair recovery from CH-induced PAH. Inhibition of heightened PDGF-Rbeta signaling is sufficient to reverse PAH in this genetic model.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19801450      PMCID: PMC2793182          DOI: 10.1152/ajplung.00199.2009

Source DB:  PubMed          Journal:  Am J Physiol Lung Cell Mol Physiol        ISSN: 1040-0605            Impact factor:   5.464


  47 in total

Review 1.  The PPARs: from orphan receptors to drug discovery.

Authors:  T M Willson; P J Brown; D D Sternbach; B R Henke
Journal:  J Med Chem       Date:  2000-02-24       Impact factor: 7.446

2.  Angiopoietin/Tie2 pathway influences smooth muscle hyperplasia in idiopathic pulmonary hypertension.

Authors:  Laurence Dewachter; Serge Adnot; Elie Fadel; Marc Humbert; Bernard Maitre; Anne-Marie Barlier-Mur; Gerald Simonneau; Michel Hamon; Robert Naeije; Saadia Eddahibi
Journal:  Am J Respir Crit Care Med       Date:  2006-08-17       Impact factor: 21.405

3.  PPARgamma in endothelial cells influences high fat diet-induced hypertension.

Authors:  Christopher J Nicol; Masahiro Adachi; Taro E Akiyama; Frank J Gonzalez
Journal:  Am J Hypertens       Date:  2005-04       Impact factor: 2.689

4.  Disruption of endothelial peroxisome proliferator-activated receptor-gamma reduces vascular nitric oxide production.

Authors:  Jennifer M Kleinhenz; Dean J Kleinhenz; Shaojin You; Jeffrey D Ritzenthaler; Jason M Hansen; David R Archer; Roy L Sutliff; C Michael Hart
Journal:  Am J Physiol Heart Circ Physiol       Date:  2009-08-07       Impact factor: 4.733

5.  Overexpression of the serine elastase inhibitor elafin protects transgenic mice from hypoxic pulmonary hypertension.

Authors:  Syed H E Zaidi; Xiao-Mang You; Sorana Ciura; Mansoor Husain; Marlene Rabinovitch
Journal:  Circulation       Date:  2002-01-29       Impact factor: 29.690

6.  Calmodulin-independent nitric oxide synthase from rat polymorphonuclear neutrophils.

Authors:  Y Yui; R Hattori; K Kosuga; H Eizawa; K Hiki; S Ohkawa; K Ohnishi; S Terao; C Kawai
Journal:  J Biol Chem       Date:  1991-02-25       Impact factor: 5.157

7.  Platelet-derived growth factor expression and function in idiopathic pulmonary arterial hypertension.

Authors:  Frédéric Perros; David Montani; Peter Dorfmüller; Ingrid Durand-Gasselin; Colas Tcherakian; Jérôme Le Pavec; Michel Mazmanian; Elie Fadel; Sacha Mussot; Olaf Mercier; Philippe Hervé; Dominique Emilie; Saadia Eddahibi; Gérald Simonneau; Rogério Souza; Marc Humbert
Journal:  Am J Respir Crit Care Med       Date:  2008-04-17       Impact factor: 21.405

Review 8.  The role of peroxisome proliferator-activated receptor gamma in colon cancer and inflammatory bowel disease.

Authors:  Arthur W Bull
Journal:  Arch Pathol Lab Med       Date:  2003-09       Impact factor: 5.534

9.  PPARgamma in the endothelium regulates metabolic responses to high-fat diet in mice.

Authors:  Takeshi Kanda; Jonathan D Brown; Gabriela Orasanu; Silke Vogel; Frank J Gonzalez; Juliano Sartoretto; Thomas Michel; Jorge Plutzky
Journal:  J Clin Invest       Date:  2008-12-08       Impact factor: 14.808

Review 10.  Roles of PPARs on regulating myocardial energy and lipid homeostasis.

Authors:  Qinglin Yang; Yuhao Li
Journal:  J Mol Med (Berl)       Date:  2007-03-14       Impact factor: 5.606

View more
  71 in total

Review 1.  PPARgamma as a potential therapeutic target in pulmonary hypertension.

Authors:  Roy L Sutliff; Bum-Yong Kang; C Michael Hart
Journal:  Ther Adv Respir Dis       Date:  2010-06       Impact factor: 4.031

2.  The adaptor protein Shc integrates growth factor and ECM signaling during postnatal angiogenesis.

Authors:  Daniel Timothy Sweet; Zhongming Chen; David M Wiley; Victoria L Bautch; Ellie Tzima
Journal:  Blood       Date:  2011-11-16       Impact factor: 22.113

Review 3.  Cellular and molecular aspects of vascular dysfunction in systemic sclerosis.

Authors:  Maria Trojanowska
Journal:  Nat Rev Rheumatol       Date:  2010-06-29       Impact factor: 20.543

4.  Adiponectin decreases pulmonary arterial remodeling in murine models of pulmonary hypertension.

Authors:  Meiqian Weng; Michael J Raher; Patricio Leyton; Terry P Combs; Philipp E Scherer; Kenneth D Bloch; Benjamin D Medoff
Journal:  Am J Respir Cell Mol Biol       Date:  2010-11-12       Impact factor: 6.914

5.  Autocrine fibroblast growth factor-2 signaling contributes to altered endothelial phenotype in pulmonary hypertension.

Authors:  Ly Tu; Laurence Dewachter; Benoit Gore; Elie Fadel; Philippe Dartevelle; Gérald Simonneau; Marc Humbert; Saadia Eddahibi; Christophe Guignabert
Journal:  Am J Respir Cell Mol Biol       Date:  2010-10-29       Impact factor: 6.914

6.  Ectopic upregulation of membrane-bound IL6R drives vascular remodeling in pulmonary arterial hypertension.

Authors:  Yuichi Tamura; Carole Phan; Ly Tu; Morane Le Hiress; Raphaël Thuillet; Etienne-Marie Jutant; Elie Fadel; Laurent Savale; Alice Huertas; Marc Humbert; Christophe Guignabert
Journal:  J Clin Invest       Date:  2018-04-09       Impact factor: 14.808

7.  Neprilysin regulates pulmonary artery smooth muscle cell phenotype through a platelet-derived growth factor receptor-dependent mechanism.

Authors:  Vijaya Karoor; Masahiko Oka; Sandra J Walchak; Louis B Hersh; York E Miller; Edward C Dempsey
Journal:  Hypertension       Date:  2013-02-04       Impact factor: 10.190

8.  Chronic inhibition of PPAR-γ signaling induces endothelial dysfunction in the juvenile lamb.

Authors:  Shruti Sharma; Jubilee Barton; Ruslan Rafikov; Saurabh Aggarwal; Hsuan-Chang Kuo; Peter E Oishi; Sanjeev A Datar; Jeffrey R Fineman; Stephen M Black
Journal:  Pulm Pharmacol Ther       Date:  2012-12-17       Impact factor: 3.410

9.  The Nox4 inhibitor GKT137831 attenuates hypoxia-induced pulmonary vascular cell proliferation.

Authors:  David E Green; Tamara C Murphy; Bum-Yong Kang; Jennifer M Kleinhenz; Cédric Szyndralewiez; Patrick Page; Roy L Sutliff; C Michael Hart
Journal:  Am J Respir Cell Mol Biol       Date:  2012-08-16       Impact factor: 6.914

10.  Sildenafil inhibits hypoxia-induced transient receptor potential canonical protein expression in pulmonary arterial smooth muscle via cGMP-PKG-PPARγ axis.

Authors:  Jian Wang; Kai Yang; Lei Xu; Yi Zhang; Ning Lai; Hua Jiang; Yajie Zhang; Nanshan Zhong; Pixin Ran; Wenju Lu
Journal:  Am J Respir Cell Mol Biol       Date:  2013-08       Impact factor: 6.914

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.